Straits Times Index
3,292.69 +10.64 (+0.32%) Nikkei
38,139.60 -134.45 (-0.35%) Hang Seng
17,763.03 +16.12 (+0.09%) FTSE 100
8,121.24 -22.89 (-0.28%) Bitcoin USD
57,817.96 -2,372.59 (-3.94%) CMC Crypto 200
1,267.28 -71.79 (-5.36%)
Swedish Orphan Biovitrum AB (publ) (BIOVF)
| Previous close | 22.87 |
| Open | 23.74 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 22.87 - 22.87 |
| 52-week range | 18.35 - 27.79 |
| Volume | |
| Avg. volume | 88 |
| Market cap | 8.865B |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | 39.43 |
| EPS (TTM) | 0.58 |
| Earnings date | 16 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireSobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.
PR NewswireSobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
PR NewswireNotice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Tuesday, 14 May 2024 at 15.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.
